Hypertension is India's most prevalent non-communicable disease. The India Hypertension Control Initiative (IHCI) estimates that over 220 million Indian adults have hypertension, yet fewer than 15% have it under control. For Indian doctors, high blood pressure is the single most common chronic condition managed in outpatient settings — and in 2026, both the diagnostic thresholds and treatment protocols have evolved significantly. Search data confirms that Indian doctors are actively looking for updated answers: What is the new BP target? When should you start combination therapy? What counts as resistant hypertension? Which drug class is best for Indian patients? This guide answers all of that without fluff. Updated Blood Pressure Targets for Indian Patients in 2026 The 2018 ACC/AHA guidelines lowered the hypertension threshold to ≥130/80 mmHg, and most Indian societies including the Cardiological Society of India (CSI) have broadly aligned with this. In 2026, the consensus for Indian clinical practice is: General adults: Target <130/80 mmHg if tolerated Elderly (≥65 years): Target <140/90 mmHg (individualize based on frailty and comorbidities) Diabetes with HTN: Target <130/80 mmHg CKD with proteinuria: Target <130/80 mmHg (with ACE inhibitor or ARB as preferred agent) Post-stroke/TIA: Target <130/80 mmHg to prevent recurrence Key clinical note: In Indian patients, orthostatic hypotension is common, especially in elderly and diabetic patients. Always check standing BP before intensifying therapy in these groups. First-Line Drug Selection: What Works Best in Indian Patients Indian patients have distinct pharmacogenomic characteristics that affect drug response. The renin-angiotensin system tends to be less active compared to Western populations, which means that ACE inhibitors and ARBs are less potent as monotherapy in some Indian patients — particularly those of Dravidian ethnicity. The following is the evidence-based drug selection framework for Indian HTN: Stage 1 HTN (130–139/80–89 mmHg) with High CV Risk, or Stage 2 HTN (≥140/90 mmHg) Start with combination therapy: ACE inhibitor (or ARB) + calcium channel blocker (CCB). This is now the preferred initial approach for most Indian patients with stage 2 hypertension, supported by the VALUE and ACCOMPLISH trials. Single-pill combination (SPC) formulations like telmisartan + amlodipine have superior adherence data in Indian populations. CCBs as First-Line for Isolated Systolic Hypertension Amlodipine 5–10 mg OD is highly effective for isolated systolic hypertension, which is the predominant pattern in elderly Indian patients. It is cheap, once-daily, and has robust cardiovascular outcome data. Pedal oedema is the main side effect — mitigated by combining with an ACE inhibitor/ARB. Diuretics: When and Which One Chlorthalidone is superior to hydrochlorothiazide (HCTZ) in head-to-head trials and is the preferred thiazide-like diuretic. In Indian patients with salt-sensitive hypertension (very common in southern India and with a positive family history), adding chlorthalidone 12.5–25 mg as a third agent is highly effective. Indapamide SR is a metabolically neutral alternative. Resistant Hypertension: Definition, Workup, and Treatment Resistant hypertension is defined as BP that remains above target despite optimal or maximally tolerated doses of 3 antihypertensive drugs (including a diuretic). Before labelling a patient resistant, always rule out: Non-adherence — the most common cause of apparent resistance in Indian patients (pill burden, cost, side effects) White-coat effect — confirm with home BP monitoring or 24-hour ABPM Drug interactions (NSAIDs, COX-2 inhibitors, oral contraceptives, decongestants) Secondary hypertension (primary aldosteronism, renal artery stenosis, obstructive sleep apnea, phaeochromocytoma) For true resistant hypertension, add spironolactone 25–50 mg as the 4th agent — this is now a Grade A recommendation supported by the PATHWAY-2 trial. It is particularly effective in India where primary aldosteronism is under-diagnosed. Monitor potassium and eGFR carefully. The Role of Home BP Monitoring and ABPM in Indian Practice Home blood pressure monitoring (HBPM) is now endorsed by all major guidelines as a cornerstone of HTN management. Indian data shows that white-coat hypertension affects up to 30% of patients referred for HTN — this is clinically important because it can lead to unnecessary treatment. Recommend patients measure BP twice in the morning and twice in the evening for 7 days, discarding day-1 readings, and average the remaining values (the '722 protocol'). Ambulatory blood pressure monitoring (ABPM) remains the gold standard for diagnosing masked hypertension, white-coat HTN, and non-dipping patterns — each with distinct cardiovascular prognosis. Consider ABPM before starting treatment in low-to-moderate risk patients with borderline clinic BP. Hypertension and Comorbidities: Tailoring Treatment in Indian Patients HTN + Type 2 Diabetes ACE inhibitor or ARB is mandatory as first-line — it reduces both CV risk and nephropathy progression. Target BP <130/80 mmHg. Avoid beta-blockers as first-line in diabetic HTN unless heart failure or angina is present, as they mask hypoglycaemia and worsen insulin resistance. HTN + CKD ACE inhibitor or ARB is renoprotective and reduces proteinuria. Do not combine ACE inhibitor + ARB (dual RAS blockade) — this increases AKI and hyperkalaemia risk without outcome benefit. Add SGLT2 inhibitors (empagliflozin, dapagliflozin) in CKD with eGFR >20 for both BP reduction and nephroprotection. HTN + Heart Failure The GDMT combination of ACE inhibitor/ARB/ARNI + beta-blocker + MRA + SGLT2 inhibitor is both heart failure treatment and blood pressure management. Beta-blockers (carvedilol, bisoprolol, metoprolol succinate) are first-line antihypertensives in HFrEF. Avoid CCBs in HFrEF. Lifestyle Interventions That Actually Move the BP Needle in India Sodium restriction: Reduce to <5g/day of salt (2g sodium). Indian diet typically contains 8–10g/day. Each 2.3g reduction in sodium lowers SBP by 5–6 mmHg. DASH diet: Rich in fruits, vegetables, low-fat dairy, potassium. Reduces BP by 8–11 mmHg. Adapt to Indian food patterns — focus on reducing pickles, papads, packaged foods. Physical activity: 150 minutes of moderate aerobic activity per week reduces SBP by 4–9 mmHg. Yoga has emerging evidence for BP reduction in Indian patients. Weight loss: Each 1 kg reduction in body weight lowers BP by approximately 1 mmHg. Alcohol restriction: Reduce to <2 standard drinks/day for men, <1 for women. Binge drinking patterns common in India cause significant BP spikes. Frequently Asked Questions: Hypertension in India Is 130/80 mmHg now the new hypertension threshold in India? Most Indian cardiology societies have aligned with the 2018 ACC/AHA definition of hypertension as ≥130/80 mmHg. However, the practical implication depends on cardiovascular risk. Stage 1 HTN (130–139/80–89 mmHg) in low-risk individuals is managed with lifestyle changes first; pharmacotherapy is initiated if there is existing CVD, diabetes, CKD, or 10-year ASCVD risk ≥10%. Which antihypertensive drug is best for Indian patients? There is no single best drug. The evidence-based first choice for most Indian patients without specific comorbidities is an ACE inhibitor/ARB + amlodipine combination. For high-sodium diets and salt-sensitive hypertension, adding chlorthalidone improves control. Telmisartan is a commonly preferred ARB in India due to its 24-hour coverage and metabolic neutrality. When should combination therapy be started upfront in HTN? Current evidence supports starting with dual combination therapy (rather than sequential monotherapy) for most Stage 2 hypertension patients and all patients with Stage 1 HTN + high CV risk. The advantages are faster BP control, lower rates of adverse effects (by using lower doses of each drug), and better adherence with single-pill combinations. The old 'start low, go slow' monotherapy approach is now reserved for Stage 1 HTN in low-risk patients and the elderly. What causes hypertension to be so poorly controlled in India? The IHCI's own data points to three systemic failures: under-diagnosis (nearly half of hypertensives don't know their status), under-treatment (doctors often start with monotherapy when combination is needed), and poor adherence (pill burden, cost, no symptoms so patients feel no urgency). The 'silent killer' nature of HTN is its biggest barrier to control in India — patients who feel well don't take daily medication seriously. Can hypertension be cured with lifestyle changes alone? In Stage 1 HTN with no target organ damage or high CV risk, a 3–6 month trial of aggressive lifestyle modification is appropriate before initiating drugs. Some patients with salt-sensitive hypertension normalise their BP with sodium restriction and weight loss. However, for patients with Stage 2 HTN, established CVD, diabetes, or CKD, drug therapy is non-negotiable and should not be delayed in the hope that lifestyle changes alone will suffice. Is telmisartan better than losartan? Telmisartan has the longest half-life among ARBs (24 hours) and provides more consistent 24-hour BP control, particularly the morning BP surge. The ONTARGET trial confirmed its non-inferiority to ramipril in high-risk patients. In clinical practice, telmisartan is preferred for patients with documented morning hypertension or non-dipping pattern on ABPM, and in those with metabolic syndrome due to its PPAR-γ agonist activity. What is the role of renal denervation in resistant hypertension? Renal denervation has seen a resurgence following the SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED trials, which showed meaningful BP reductions. It is now CE-marked in Europe and available in select Indian centres for true resistant hypertension. It is not a first-line option — reserve it for patients in whom 4+ drug combinations have failed and secondary causes have been excluded. Cost and access remain limiting factors in India. How DocTrust Helps Indian Doctors Win the Battle Against Hypertension With over 220 million Indian patients living with hypertension, the challenge is not just about prescribing the right drug — it is about ensuring that patients actually follow through on treatment and monitoring. DocTrust's AI-powered platform helps clinics build structured HTN care protocols: automated reminders for BP check follow-ups, digital prescription tracking to monitor adherence patterns, and OPD analytics that flag patients who haven't visited in 3 or 6 months. The WhatsApp automation feature sends patients periodic reminders about home BP logging and prescription refills — addressing the single biggest failure point in Indian HTN management: adherence. See how DocTrust can transform chronic disease care at your clinic. Get your free demo today at www.doctrust.in.